glutathione pharmacokinetics plasma half-life PDF) of and Its Metabolites in Normal Subjects Enhancing the Oral Bioavailability of

Regulatory Note on Injectable GHK-Cu It is important to note that the FDA added injectable GHK-Cu to a high-risk compounded substance list in September 2023

Store lyophilized material at 4 F (20 C) or below Allow vial to reach room temperature before opening Protect from light, heat, and humidity Use sterile laboratory equipment during preparation Avoid repeated freezethaw cycles Label reconstituted samples with preparation date and concentration These practices support consistent experimental outcomes and reduce variability across assays

Once-weekly dosing is convenient

CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process